Cemiplimab‐rwlc in advanced cutaneous squamous cell carcinoma: real‐world experience in a French dermatology department
- 9 June 2021
- journal article
- letter
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 185 (5), 1056-1058
- https://doi.org/10.1111/bjd.20569
Abstract
Cemiplimab-rwlc (CEMI), a programmed cell death protein 1 (PD-1) inhibitor, has demonstrated its efficacy for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) patients that has never been reported with chemotherapy and is currently recommended for the first-line treatment of patients with advanced CSCC by the European guidelines2. However, real-life data and long-term survival data are lacking.This publication has 9 references indexed in Scilit:
- Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell CarcinomasJournal of Clinical Oncology, 2020
- Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter studyEuropean Journal of Cancer, 2020
- Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosingJournal for ImmunoTherapy of Cancer, 2020
- European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. TreatmentEuropean Journal of Cancer, 2020
- Where do we stand with immune checkpoint blockade for advanced cutaneous squamous cell carcinoma? A systematic review and critical appraisal of the existing evidenceBritish Journal of Dermatology, 2020
- Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trialThe Lancet Oncology, 2020
- Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up.Journal of Clinical Oncology, 2019
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaThe New England Journal of Medicine, 2018
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burdenGenome Medicine, 2017